Gil Morgan, MD· @weoncologists · X·· 4 天前评分90
正文 · 机器翻译
三联疗法并不总能战胜双联疗法！
LITESPARK-012：使用 belzutifan 或 MK-1308A 并未带来 PFS 或 OS 获益，仅增加了停药情况。这是一项重要的 1L RCC 阴性 III 期研究。#ESMO26 #KidneyCancer
783 浏览 · 7 赞 · 6 转发 · 1 回复
OncoAlert 4Sight Abstracts to be Presented at #ESMO26 First-Line Pembrolizumab + Lenvatinib + Belzutifan or MK-1308A + Lenvatinib in Advanced RCC: The Randomized Open-Label Phase 3 LITESPARK-012 Study @DrChoueiri @tompowles1 @MVossMD @ERPlimackMD @HowardGurney @brian_rini 🔬 Phase 3 (n=1688), untreated advanced ccRCC: pembrolizumab + lenvatinib + belzutifan (Arm A) or MK-1308A + lenvatinib (Arm B) vs pembrolizumab + lenvatinib. Dual primary: PFS by BICR and OS. ➡️ Arm A: PFS HR 1.08 (0.93–1.26); OS HR 1.04 (0.87–1.25) ➡️ Arm B: PFS HR 1.07 (0.92–1.25); OS HR 1.12 (0.94–1.35) ➡️ Discontinuation due to AEs: 51.6% (A), 51.4% (B), 36.2% (control) ✅ Neither belzutifan nor CTLA-4 blockade added to pembrolizumab + lenvatinib improved efficacy; pembrolizumab + lenvatinib remains a 1L SOC. #KidneyCancer 🎙️ Toni Choueiri 👥 Thomas Powles · Martin Voss · Elizabeth Plimack · Howard Gurney · Yue Song · Rodolfo Perini · Karla Rodriguez-Lopez · Brian Rini (4Sight Made solely from Abstracts publicly available at the ESMO website) Pinging Our Faculty @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper在 X 查看被引用的帖子
帖内回复
- MeDucation@MeDucationai
@weoncologists The discontinuation gap is the part fellows should remember: about half of patients on either triplet stopped for adverse events versus about a third on the doublet, so the extra drug cost tolerability without buying PFS or OS.
来源：Gil Morgan, MD · x.com